TP53 and Thrombocytopenia: In addition, recent clinical studies indicate that a second-generation potent and selective MDM2 antagonist (i.e., Idasanutlin) can have a markedly beneficial impact on p53 activation in leukemic patients, yet along with common adverse side effects such as diarrhoea, nausea/vomiting and, in some cases, myelosuppression causing febrile neutropenia and thrombocytopenia, possibly caused by an on-target impact on normal cells (Konopleva et al., 2020).